Rapamycin (Sirolimus) and Finasteride Interaction

Pharmacokinetic Basis of the Interaction

Both sirolimus and finasteride undergo hepatic metabolism through the cytochrome P450 3A4 enzyme system, but their interaction at this site is pharmacokinetically minor.

Sirolimus is extensively metabolized by CYP3A4 and is also a substrate of P-glycoprotein (P-gp) in the intestinal wall and liver [1]. Its bioavailability is approximately 14% in healthy volunteers, and it has a long terminal half-life of 57 to 63 hours [2]. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin) can increase sirolimus area-under-the-curve (AUC) by 4- to 11-fold, which is why the FDA label carries explicit warnings about these combinations [1].

Finasteride, by contrast, is metabolized by CYP3A4 but does not inhibit or induce the enzyme at therapeutic concentrations [3]. The 1 mg dose used for androgenetic alopecia and the 5 mg dose used for benign prostatic hyperplasia both undergo hepatic biotransformation to inactive metabolites without meaningful effects on CYP3A4 activity in vivo [3]. No published pharmacokinetic study has demonstrated that finasteride alters the clearance of any CYP3A4 substrate.

This asymmetry matters. A true pharmacokinetic interaction requires one drug to alter the metabolism of the other. Because finasteride lacks inhibitory or inducing properties at CYP3A4, it does not raise sirolimus trough concentrations in the way that azole antifungals or macrolide antibiotics do.

P-Glycoprotein Considerations

Sirolimus depends on intestinal P-gp efflux to limit its oral absorption. Drugs that inhibit P-gp (cyclosporine, verapamil) substantially increase sirolimus bioavailability [1].

Finasteride has not been identified as a P-gp inhibitor or substrate in published transporter studies [3]. The International Transporter Consortium's classification does not list finasteride among clinically relevant P-gp perpetrators [4]. This means the intestinal absorption of sirolimus should remain unchanged when finasteride is co-administered.

One theoretical nuance: both drugs are highly protein-bound (sirolimus ~92% to erythrocytes and plasma proteins; finasteride ~90% to plasma albumin) [1][3]. Displacement interactions between highly bound drugs are rarely clinically significant when the displaced drug has a large volume of distribution, as sirolimus does (12 L/kg) [2]. Protein binding displacement is not expected to produce meaningful free-drug concentration changes for either agent.

Pharmacodynamic Overlap on Androgen Pathways

The more clinically relevant consideration is pharmacodynamic, not pharmacokinetic.

Sirolimus inhibits mTOR (mechanistic target of rapamycin), a kinase that sits downstream of multiple growth-factor and hormonal signaling pathways. In male renal transplant recipients on full immunosuppressive doses (trough 5 to 15 ng/mL), sirolimus has been associated with decreased testosterone levels, oligospermia, and reduced sperm motility [5]. A 2012 study by Zuber et al. found that 57% of male transplant patients on sirolimus-based regimens developed testosterone levels below the reference range [5].

Finasteride blocks type II 5-alpha reductase, preventing the conversion of testosterone to dihydrotestosterone (DHT). This raises serum testosterone modestly (by approximately 10 to 15%) while reducing DHT by 60 to 70% at the 1 mg dose [3].

When combined, the net hormonal effect depends heavily on the sirolimus dose:

Full immunosuppressive dosing (trough 5-15 ng/mL): Sirolimus-induced testosterone suppression plus finasteride-mediated DHT reduction could produce a compounded androgen-deficit state. Symptoms might include decreased libido, erectile dysfunction, fatigue, or mood changes. This population warrants baseline and periodic total testosterone and free testosterone measurement.

Low-dose longevity protocols (typically 1-6 mg weekly, pulsed): The intermittent, sub-immunosuppressive dosing used in longevity medicine produces minimal sustained mTOR inhibition and has not been associated with clinically significant hypogonadism in published cohorts [6]. At these doses, additive androgen suppression with finasteride 1 mg daily is unlikely to reach clinical thresholds.

Clinical Evidence and Database Classifications

No randomized controlled trial has directly studied the sirolimus-finasteride combination. The interaction does not appear in the Lexicomp, Micromedex, or Clinical Pharmacology databases as a major or contraindicated pairing.

The Drugs.com interaction checker classifies the combination as having "no known interaction" [7]. Similarly, the University of Liverpool's drug interaction database (primarily focused on transplant immunosuppression) does not flag finasteride as a perpetrator of sirolimus level changes [8].

This absence of signal is consistent with finasteride's clean CYP and transporter profile. A 2019 systematic review of sirolimus drug interactions by Zimmerman et al. cataloged 47 clinically relevant CYP3A4 perpetrators but did not include finasteride among them [9].

The FDA-approved prescribing information for Rapamune (sirolimus) lists CYP3A4 and P-gp inhibitors/inducers as interaction concerns but does not mention 5-alpha reductase inhibitors [1]. The Proscar/Propecia (finasteride) label similarly contains no warnings about mTOR inhibitors [3].

Monitoring Recommendations

Despite the low pharmacokinetic risk, rational prescribing calls for verification rather than assumption.

For transplant patients already on therapeutic sirolimus who are adding finasteride: obtain a sirolimus trough level at baseline, then repeat at 5 to 7 days and again at 14 days after initiation. If levels remain within the target window, no dose adjustment is needed.

For longevity-protocol patients on weekly pulsed rapamycin (where trough monitoring is less standardized): the primary monitoring targets are clinical. Screen for sexual side effects at 4 and 12 weeks using a validated questionnaire (IIEF-5 or Arizona Sexual Experience Scale). Check total testosterone if symptoms emerge.

Hepatic function monitoring applies to both drugs independently. Sirolimus can raise transaminases, and finasteride carries a rare signal for liver enzyme elevation [1][3]. A baseline metabolic panel with repeat at 3 months covers both agents.

Dose-Adjustment Guidance

No dose adjustment of either drug is required based on the pharmacokinetic data.

If a transplant patient's sirolimus trough rises above target range after starting finasteride (which would be unexpected and likely coincidental, perhaps from dietary changes or new medications), investigate other causes before attributing the change to finasteride. Grapefruit juice, St. John's wort cessation, or a new azole prescription are far more probable culprits.

For the specific clinical scenario of a man on low-dose rapamycin (3 to 6 mg once weekly) adding finasteride 1 mg daily for hair loss: maintain both at standard doses. The 7-day dosing interval for rapamycin means that steady-state trough levels are negligible between doses, further minimizing any interaction window.

Patient Counseling Points

Patients taking both medications should understand three things.

First, the combination is not contraindicated. No regulatory body or major interaction database flags it as dangerous. The absence of a formal interaction study reflects the low clinical concern, not a knowledge gap that implies hidden danger.

Second, both drugs can independently affect sexual function. Finasteride causes erectile dysfunction in 1.3% and decreased libido in 1.8% of men at the 1 mg dose (versus 0.7% and 1.3% on placebo in the landmark Kaufman et al. trial, N=1,553) [10]. Sirolimus at immunosuppressive doses has a higher rate of sexual dysfunction, reported in 5 to 11% of male transplant recipients [5]. If sexual side effects emerge, determining which drug is responsible requires sequential withdrawal or dose reduction.

Third, for patients using rapamycin off-label for longevity: the evidence base for this indication comes primarily from murine lifespan studies and small human biomarker trials [6]. The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial is ongoing and has not yet reported primary outcomes [11]. Adding finasteride to an already off-label regimen does not compound medical risk meaningfully, but patients should acknowledge the investigational nature of their protocol.

Special Populations

Post-transplant patients: The combination is most relevant in renal transplant recipients who develop androgenetic alopecia (common with immunosuppressive regimens) and request finasteride. These patients are already under close pharmacokinetic monitoring. Adding finasteride is straightforward from an interaction standpoint but requires attention to the cumulative androgen-suppression effect described above.

Women: Finasteride is contraindicated in women of childbearing potential due to teratogenicity (FDA Pregnancy Category X) [3]. Sirolimus also carries reproductive toxicity warnings [1]. This combination should not arise in premenopausal women.

Elderly men: Age-related decline in CYP3A4 activity could theoretically slow sirolimus clearance. However, finasteride does not alter this trajectory, so the interaction profile remains unchanged in older patients. Standard age-based dosing applies to both drugs independently.

Comparison with Other Rapamycin Interactions

To contextualize severity: the sirolimus-finasteride pairing is negligible compared to established dangerous combinations.

Sirolimus plus ketoconazole increases sirolimus AUC by 10.9-fold [1]. Sirolimus plus diltiazem increases AUC by 1.6-fold [1]. Sirolimus plus rifampin decreases AUC by 82% [1]. These are clinically significant interactions requiring mandatory dose changes or avoidance.

Sirolimus plus finasteride has no documented AUC change. It falls into the same low-risk category as sirolimus with acetaminophen or sirolimus with omeprazole: theoretically sharing some metabolic machinery but producing no measurable pharmacokinetic consequence at therapeutic doses.

Summary of Clinical Decision Framework

The rapamycin-finasteride combination is pharmacokinetically benign and pharmacodynamically manageable. Prescribers should confirm stable sirolimus levels after adding finasteride (especially in transplant patients), monitor for additive sexual side effects, and reassess if symptoms of androgen deficiency develop. No dose adjustment is indicated for either drug based on the co-prescription alone.

The 2023 Endocrine Society guidelines on testosterone therapy recommend checking total testosterone in any man reporting new sexual dysfunction on medications known to affect the androgen axis [12]. This applies to the sirolimus-finasteride combination in symptomatic patients.

Baseline sirolimus trough, total testosterone, and hepatic panel before initiating the combination provides a complete safety net for the prescriber managing both drugs simultaneously.